Cardinal Health announced it now expects to generate more than $50 billion in specialty revenue for fiscal 2026, up from its previous internal estimate of $48 billion. This increase reflects robust demand across oncology, immunology and rare diseases, driven by the company’s expanded specialty pharmacy network and recent distribution agreements. Management highlighted that specialty products now represent approximately 35 percent of total revenue, up from 32 percent in fiscal 2024, and reiterated its commitment to investing in clinical support services that boost margin performance in this high-growth segment.

On Tuesday, Cardinal Health raised its fiscal 2026 adjusted earnings per share forecast to at least $10.00, compared with its prior guidance range of $9.65 to $9.85 per share. The upward revision reflects cost savings achieved through supply chain optimization programs and lower-than-anticipated logistics expenses following the implementation of new inventory management systems. The company confirmed that gross margin should improve by 50 basis points year-over-year, driven by favorable product mix and reduced distribution center inefficiencies.

Despite ongoing macroeconomic headwinds, Cardinal Health’s scale and operational discipline continue to distinguish it from peers. In the recent third quarter, the company reported 4 percent organic revenue growth, outpacing the broader medical supplies sector by 150 basis points. Leadership pointed to successful cross-selling initiatives between its pharmaceutical and medical products businesses, as well as ongoing enhancements to its data analytics platform, which have reduced customer order-to-delivery times by 12 percent. These factors underpin management’s confidence that CAH can deliver total shareholder returns in the top quartile of its sector over the next three years.